NCT00417261

Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of Single and Multiple-Doses of ATF936 and AXT914 Administered Orally in Healthy Subjects.

A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Ascending Single and Multiple Dose, Seamless Design Study to Explore the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Orally Administered Compounds, ATF936 and AXT914, in Healthy Male and Female Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 65 (estimated)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 18 Years – 68 Years
• Healthy volunteers: Accepted

Summary

This is a first-in-human study and is designed to evaluate the safety, tolerability, pharmacodynamic and pharmacokinetic effects of a single and multiple-doses of ATF936 and AXT914 administered orally in healthy subjects.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	ATF936
DRUG	AXT914

Timeline

• Start date: 2006-11-01
• Completion: 2008-04-01
• First posted: 2006-12-29
• Last updated: 2008-06-23

Locations

1 site across 1 country: United States